UK markets open in 2 hours 58 minutes
NIKKEI 225
38,261.06 -12.99 (-0.03%) HANG SENG
18,119.17 +356.14 (+2.00%) CRUDE OIL
79.44 +0.44 (+0.56%) GOLD FUTURES
2,328.10 +17.10 (+0.74%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,813.12 -2,205.11 (-4.59%)
Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)
BSE - BSE Real-time price. Currency in INR
Add to watchlist
As of 09:17AM IST. Market open.
| Previous close | 1,502.30 |
| Open | 1,504.60 |
| Bid | 1,508.50 x 0 |
| Ask | 1,510.90 x 0 |
| Day's range | 1,503.00 - 1,512.00 |
| 52-week range | 922.55 - 1,638.70 |
| Volume | |
| Avg. volume | 117,415 |
| Market cap | 3.628T |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 40.74 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 12.50 (0.83%) |
| Ex-dividend date | 09 Feb 2024 |
| 1y target est | N/A |
- Globe Newswire
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming intern
© 2024 Yahoo. All rights reserved.